TARA HUNKE: Open Payments
NPI 1346512597 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$210 in 12 payments from 9 companies in 2025. Trend: 2023 $1,596 · 2024 $1,408 · 2025 $210
Food & beverage: $210
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $47 |
| Pharmacosmos Therapeutics Inc. | 2 | $43 |
| Novartis Pharmaceuticals Corporation | 1 | $23 |
| Eisai Inc. | 1 | $20 |
| PUMA BIOTECHNOLOGY, INC. | 1 | $16 |
| AVYXA PHARMA, LLC | 1 | $16 |
| Gilead Sciences, Inc. | 1 | $15 |
| Octapharma USA, Inc. | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
Products named: MONOFERRIC, PLUVICTO, Lenvima, LUPRON DEPOT, NERLYNX, CYCLOPHOSPHAMIDE, LINZESS, Trodelvy.
Industry payments across NE — which companies pay providers there.
